Overview

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Status:
Unknown status

Trial end date:
2021-04-15

Target enrollment:

Participant gender:

Summary

The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.